In this article
Stage IIIb Non-Small Cell Lung Cancer Diagnosis and Initial Treatment
In December 2007, Ms. 54, who had aggravated hemoptysis for 2 months, lost weight, lost appetite, and had bone pain. A CT chest scan revealed a 9 cm x 5.8 cm x 7.2 cm “large, lobulated, heterogeneously enhanced mass” in the left lower lobe of the lung. In addition, another smaller needle-like lesion was found in the upper left lobe.
Later, biopsy confirmed invasive, moderately differentiated lung squamous cell carcinoma. A CT scan showed involvement of the chest wall muscles and had metastasized. Her bone scan was negative (no metastases). Therefore, she was diagnosed with T4N1M0-IIIb stage non-small cell lung cancer.
In 3 months, Ms. M was treated with paclitaxel (260 mg) and carboplatin (415 mg) for 3 cycles. This shrinks the tumor to 7 cm x 6 cm x 5 cm. Later, chemoradiotherapy was performed in parallel with 2 cycles of cisplatin (50 mg) and 60 Gy of radiation.
CIMAvax Lung Cancer Vaccine Efficacy and Long-Term Survival
Two months after the completion of chemoradiotherapy, Ms. M learned that there was a clinical trial of a lung cancer vaccine and decided to receive CIMAvax vaccine after thinking about it.
80% of people who received cyclophosphamide treatment before CIMAvax injection showed some anti-EGF activity. Vaccination at multiple sites will further increase effectiveness.
A preoperative CT scan showed a 3 cm x 3 cm lesion in the lower lobe (Figure 1). Left upper lobe lesions were less than 1 cm in diameter, and localized pleural effusion was secondary to radiotherapy.
After 3 months of CIMAvax lung cancer vaccine treatment, the tumor shrank to 2 cm x 2.1 cm
By 6 months of treatment, the tumor had shrunk from its original volume by 30% to 1.5 cm x 2.3 cm before stabilization. At this time, her pleural effusion continued to decrease, and her local lymph nodes became smaller.
During the first 16 shots, Ms. M did not experience any side effects. Within minutes of the 17th injection, her waist pain had “ increased ” and was considered a vaccine-related Grade 3 response. Symptoms subsided after 10 minutes of treatment with 10 mg of chlorpheniramine, 200 mg of hydrocortisone and 50 mg of tramadol.
Later, she decided to stop treatment with the CIMAvax vaccine. A chest CT scan was performed three months after stopping treatment (18 months after starting CIMAvax treatment). Six months have passed since her last scan, and there has been no “significant change” in tumor size (Figure 3), and her condition has remained stable.
At the last follow-up-28 months after stopping the vaccination-the women’s FNM was in good condition and healthy and stable. Her ECOG status has remained at 0 (best). At this point, she has survived 48 months since her diagnosis and her condition remains stable.
Ms. M ’s lung cancer vaccine was approved for marketing in Cuba in 2008 for maintenance treatment of stage IIIB-IV non-surgical advanced non-small cell lung cancer (NSCLC). This is the first registration of a therapeutic vaccine in Cuba and the first registration of a lung cancer vaccine in the world.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.